104 related articles for article (PubMed ID: 33355863)
21. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
22. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
23. Expression of p53 in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
25. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
[TBL] [Abstract][Full Text] [Related]
26. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
27. Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors.
Sturgeon SR; Sherman ME; Kurman RJ; Berman ML; Mortel R; Twiggs LB; Barrett RJ; Wilbanks GD; Brinton LA
Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):231-5. PubMed ID: 9521439
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas.
Al-Maghrabi J; Abdelrahman AS; Ghabrah T; Butt NS; Al-Maghrabi B; Khabaz MN
Pathol Res Pract; 2017 Apr; 213(4):348-352. PubMed ID: 28215640
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression.
Shih HC; Shiozawa T; Miyamoto T; Kashima H; Feng YZ; Kurai M; Konishi I
Anticancer Res; 2004; 24(6):3843-50. PubMed ID: 15736420
[TBL] [Abstract][Full Text] [Related]
30. RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma.
Liu S; Lin M; Ji H; Ding J; Zhu J; Ma R; Meng F
Diagn Pathol; 2019 Jan; 14(1):7. PubMed ID: 30684972
[TBL] [Abstract][Full Text] [Related]
31. Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer.
Laas E; Ballester M; Cortez A; Gonin J; Daraï E; Graesslin O
Gynecol Oncol; 2014 May; 133(2):205-10. PubMed ID: 24556060
[TBL] [Abstract][Full Text] [Related]
32. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
33. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
34. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
35. SPECIFICITIES OF ENDOMETRIAL PROLIFERATION/STEM CELL INDEX DISTRIBUTION IN ENDOMETRIOID CARCINOMA OF DIFFERENT GRADE OF MALIGNANCY.
Kikalishvili N; Beriashvili R; Muzashvili T; Burkadze G
Georgian Med News; 2018 Mar; (276):117-123. PubMed ID: 29697394
[TBL] [Abstract][Full Text] [Related]
36. Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis.
Geels YP; Pijnenborg JM; van den Berg-van Erp SH; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Obstet Gynecol; 2012 Nov; 120(5):1124-31. PubMed ID: 23090531
[TBL] [Abstract][Full Text] [Related]
37. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
38. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
Ramalingam P; Masand RP; Euscher ED; Malpica A
Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
[TBL] [Abstract][Full Text] [Related]
39. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
